CN108947914A - Fluoxastrobin acetic acid solvate and preparation method - Google Patents
Fluoxastrobin acetic acid solvate and preparation method Download PDFInfo
- Publication number
- CN108947914A CN108947914A CN201810573514.4A CN201810573514A CN108947914A CN 108947914 A CN108947914 A CN 108947914A CN 201810573514 A CN201810573514 A CN 201810573514A CN 108947914 A CN108947914 A CN 108947914A
- Authority
- CN
- China
- Prior art keywords
- fluoxastrobin
- acetic acid
- solvate
- solvent
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to Fluoxastrobin acetic acid solvates and preparation method thereof.Its X-ray powder diffraction collection has characteristic peak in 2 θ=7.40 ± 0.20 ° of the angle of diffraction, 8.28 ± 0.20 °, 13.26 ± 0.20 °, 14.07 ± 0.20 °, 14.52 ± 0.20 °, 18.08 ± 0.20 °, 18.42 ± 0.20 °, 18.86 ± 0.20 °, 20.46 ± 0.20 °, 21.18 ± 0.20 °, 22.14 ± 0.20 °, 22.68 ± 0.20 °, 24.46 ± 0.20 °, 26.88 ± 0.20 °, 28.60 ± 0.20 ° etc., wherein 7.40 ± 0.20 ° are starting peak, and the relative intensity of characteristic peak is 100% at 21.18 ± 0.20 °.Preparation method is constant temperature suspension rotating crystal method, and easy to operate, favorable reproducibility, good product mobility is not easy to coalesce, is easy to industrialize.
Description
Technical field
The invention belongs to field of medicine and chemical technology, and in particular to Fluoxastrobin acetic acid solvate and preparation method.
Background technique
Polymorphism refers to solid matter with two or more different spaces arrangement mode, and formation has not
With physicochemical properties solid state the phenomenon that.In drug research field, polymorphic includes that organic solvent closes object, hydrate
Equal multicomponents crystal form.
Polymorph in pharmaceuticals phenomenon is widely present in drug discovery process, is the intrinsic characteristic of organic micromolecule compound.
Different crystal forms have different colors, fusing point, dissolubility, dissolving out capability, reactivity, chemical stability, mechanical stability etc., this
A little physical and chemical performances or processability directly influence the safely, effectively performance of drug sometimes.Therefore, crystal form research and control
The important research content being made in drug development process.
Crystal form research includes crystal discovery and crystal form preferred two stages, in crystal discovery phase, mainly using a variety of
Crystallization means, such as fusion-crystallization, solution evaporation, rapid cooling and constant temperature suspension method method for crystallising, pass through change crystallization item
Part, solvent, temperature, speed and suspension solvent ratios etc. influence the external factor of drug crystallization, using high-throughput sample preparation
Platform, while hundreds of secondary crystallization trials are prepared, with micro-example technology of preparing and analysis means of testing, prepares and find newly
Crystal form.In the crystal form preferred stage, new crystal form technique is amplified and preparation condition is groped, hand is characterized using many kinds of solids
Section, such as X-ray diffraction, solid-state nuclear magnetic resonance, Raman spectrum, the means crystal form crystal characterization such as infrared spectroscopy, in addition, to use
DSC, TG Α, DVS, HPLC etc. carry out physical and chemical performance research to crystal form, compare the progress such as stability, machinability of different crystal forms
Research, finally selects highly preferred solid forms to be developed.
China is Pesticide use and big producer, however pesticide crystallization process and crystallographic Quality Research are paid close attention to much
Not enough, there is the Fluoxastrobin (Azoxystrobin) of " king of fungicide " title, chemical name is 3- (E) -2- [2- [6- (2- cyano
Phenoxy group) pyrimidine-4-yl oxygroup]-phenyl] -3- methoxyacrylate, molecular formula: C22H17N3O5, chemical structural formula is such as
Under:
Fluoxastrobin is methoxy acrylic bactericide, has good activity to nearly all mycota disease, can use
In gardening, agricultural (vegetable and fruit), court lawn maintenance etc..Preparation is mostly suspending agent and water dispersant.
Chinese invention patent CN103012285ACN and 101621926A describe Fluoxastrobin A, B crystal form and unbodied system
Standby, which characterizes various crystal forms by using XRPD, DSC, TGA and IR, Raman.Different crystal forms X- is indicated with 2 θ angles
Ray powder diffraction characteristic peak, the then characteristic peak of crystal form A are as follows: 6.25 ± 0.20 °, 11.0 ± 0.20 °, 13.8 ± 0.20 °, 14.4
±0.20°,17.65±0.20°,19.05±0.20°,26.4±0.20°,28.5±0.20°.Its DSC curve is at about 114 DEG C
There is an endothermic peak within the scope of~117 DEG C.Crystal form A granularity is small, and size distribution is uneven, and coalescence is serious, in purification and separation process
Easily contain impurity, filtration difficulty.The characteristic peak of crystal form B are as follows: 7.5 ± 0.20 °, 11.75 ± 0.20 °, 13.20 ± 0.20 °,
14.15±0.20°,17.1±0.20°,19.65±0.20°,23.6±0.20°；Its DSC curve is in about 101 DEG C~105 DEG C models
There is an endothermic peak in enclosing.Crystal form B stability is poor, will soon be converted into stable crystal form A in a solvent, influences to store and transport
It is defeated.It is amorphous extremely unstable, it will be converted into crystal form B at room temperature, can not store, be difficult to apply in production.Commercially available production
Product are crystal form B and A and mixture, and coalescence is serious, poor fluidity, and the dry and rate of filtration is slow, and in grinding and solvent
Transformation of crystal easily occurs, stability is poor, brings many problems to post-production and preparation.
Summary of the invention
It is an object of the present invention to: provide that a kind of new, crystallinity is high, the biggish Fluoxastrobin acetic acid solvent of granularity
Object, Fluoxastrobin granularity is small in the prior art for solution, coalesces serious problems.
The second object of the present invention is: provide preparation simplicity, favorable reproducibility, good fluidity, suitable for industrial phonetic
The preparation method of bacterium ester acetic acid solvate solves the problems, such as filtration difficulty, at high cost, low efficiency in production, fills up technology sky
It is white.
In order to solve the above technical problems, the present invention is realized by technical solution as follows:
Fluoxastrobin acetic acid solvate of the present invention, the X-ray powder diffraction obtained using Cu-K alpha ray measurement
The angle of diffraction indicated with 2 angles θ 7.40 ± 0.20 °, 8.28 ± 0.20 °, 13.26 ± 0.20 °, 14.07 ± 0.20 °, 14.52 ±
0.20°、18.08±0.20°、18.42±0.20°、18.86±0.20°、20.46±0.20°、21.18±0.20°、22.14
± 0.20 °, 22.68 ± 0.20 °, 24.46 ± 0.20 °, 26.88 ± 0.20 °, 28.60 ± 0.20 ° etc. has characteristic peak,
In 7.40 ± 0.20 ° for starting peak, 21.18 ± 0.20 ° place characteristic peak relative intensity be 100%.
The X-ray powder diffraction that Fluoxastrobin acetic acid solvate of the present invention is obtained using Cu-K alpha ray measurement is with 2 θ
The angle of diffraction that angle indicates has characteristic peak as shown in table 1 below.
The X-ray powder diffraction list of 1 Fluoxastrobin acetic acid solvate of table
Fluoxastrobin acetic acid solvate of the present invention has d- value as shown abovePreferably, the solvation
Object crystal form has feature peak intensity as shown above.
Fluoxastrobin acetic acid solvate of the present invention, which is characterized in that the X-ray powder diffraction figure of the crystal form
As shown in Figure 1.
Fluoxastrobin acetic acid solvate of the present invention, which is characterized in that the crystal form is monoclinic system, and space group is
P 21/ n, cell parameter are α=
90.00°；β=97.32 (3) °；γ=90 °, unit cell volume are
In Fluoxastrobin acetic acid solvate of the present invention, the molar ratio of Fluoxastrobin and molecular acid is 1:1, and molecular formula is
C22H17N3O5·C2H4O2, 13.0% ± 0.5% weightlessness is had before being heated to 100 DEG C.Specific thermogravimetic analysis (TGA) (TG
Α) as shown in Figure 2.
Differential scanning calorimetric analysis (DSC) map of Fluoxastrobin acetic acid solvate of the present invention is at 78.9 ± 5 DEG C
There is endothermic peak, has feature melting peak at 110.0 ± 5 DEG C.It is specific as shown in Figure 3.
According to the present invention, the infared spectrum of the Fluoxastrobin acetic acid solvate 3107,3040,1772,1705,
1408、1376、1277、947、619、510、477cm-1Etc. have characteristic peak.It is specific as shown in Figure 4.
The present invention also provides the preparation methods of Fluoxastrobin acetic acid solvate, are prepared using constant temperature suspension rotating crystal method, will be phonetic
Bacterium ester is added in acetic acid, and the mass ratio of Fluoxastrobin and solvent acetic acid is 1:0.5~4, constant temperature suspend turn a brilliant temperature be 20 DEG C~
60 DEG C, 2h~6h is stirred, generates white solid, filtering product, is drying to obtain Fluoxastrobin acetic acid solvate while hot.
The specific preparation process of Fluoxastrobin acetic acid solvate is shown in embodiment.
The third object of the present invention is: providing the purposes of the Fluoxastrobin acetic acid solvate, is used to prepare mobility
Good, the biggish not solvent-laden Fluoxastrobin compound of granularity.
Fluoxastrobin acetic acid solvate of the invention is used to prepare the biggish not solvent-laden Fluoxastrobin of good fluidity, granularity
Pure crystal-form compound.Concrete operations are by Fluoxastrobin acetic acid solvate in 60 DEG C~100 DEG C, 0.08MPa~0.1MPa condition
Lower drying obtains the not solvent-laden pure crystal-form compound of Fluoxastrobin.The solvent-free compound of the Fluoxastrobin that this method obtains can be with
The rhabdolith pattern and crystal size size of original Fluoxastrobin acetic acid solvate are kept, which is special before
The crystal form A that benefit was reported, greatly improves compared to commercial product mobility, and is not easy to coalesce.
The method that the method for the present invention uses constant temperature suspension crystallization, selected solvent are three classes solvent acetic acid, to human body low toxicity, peace
Loopful is protected；Compared to dilution crystallization technique described in patent CN101621926A, succinct easy to operate, favorable reproducibility is easy to control；Phase
The method being quenched than the reflux described in patent CN101621926A and after melting, avoids high-temperature operation, safer, and ties
Brilliant mild condition, energy consumption are lower；Products obtained therefrom of the present invention is corynebacterium crystal, and crystallinity is high, and crystalline substance is practised completely, and surface is smooth, nothing
Agglomeration phenomena improves the rate of filtration, reduces the operation difficulty in production, storage and transportational process, and scanning electron microscope (SEM) photograph is shown in
Attached drawing 5, commercial product scanning electron microscope (SEM) photograph are shown in attached drawing 6.Product of the present invention volume average particle size is 39 μm, and angle of repose is 26 °, and city
Selling small product size average grain diameter is 22 μm, and angle of repose is 50 °, and the present invention substantially increases the granularity of product, improves product
Mobility is conducive to storage and transport, ensure that the superperformance of product, improve industrial production efficiency, reduce production cost,
Pesticide producing and development is promoted preferably to serve society.Product of the present invention stability is good, easily stored.To the Fluoxastrobin second
The stability of sour solvent compound is investigated, and the Fluoxastrobin acetic acid solvate crystal form product is put into centrifuge tube, sealing
It is placed in drier, control temperature is at 25 DEG C, humidity 75%, and at 14 days, sampling carried out XRPD and TGA detection, and with the 0th
It result is compareed, and Fluoxastrobin acetic acid solvate crystal form described herein does not change as the result is shown, stability
Preferably.
Fluoxastrobin acetic acid solvate has not been reported, and present invention gained crystalline product crystalline substance practises complete, crystallinity height, granularity
Uniformly, good fluidity；It is suspended using constant temperature and is prepared by crystallisation by cooling, simple and easy to do, crystallization process is easily controllable, favorable reproducibility；
And its desolventizing can be used to prepare the pure crystal-form compound of solvent-free Fluoxastrobin, it is easy to operate, it provides a kind of novel, simple
The method of prompt, the economic not solvent-laden pure crystal-form compound of Fluoxastrobin of preparation.Product of the present invention and A, B crystal form are having the same
Bactericidal effect principle inhibits mitochondrial respiratory by the electron transmission between block cell pigment, then controls and prevents and treats
The fungi being grown on agricultural and garden crop plays the function of fungicide, and anti-with having other fungicide no interactions at present
Property, have the characteristics that efficiently, wide spectrum, protection, treat, root out, permeating, systemic activity.
Detailed description of the invention
Fig. 1 is X-ray powder diffraction (XRPD) figure of Fluoxastrobin acetic acid solvate provided by the invention；
Fig. 2 is thermogravimetic analysis (TGA) (TG) figure of Fluoxastrobin acetic acid solvate provided by the invention；
Fig. 3 is differential scanning calorimetric analysis (DSC) figure of Fluoxastrobin acetic acid solvate provided by the invention；
Fig. 4 is infrared spectroscopy (IR) figure of Fluoxastrobin acetic acid solvate provided by the invention；
Fig. 5 is scanning electron microscope (SEM) figure of Fluoxastrobin acetic acid solvate provided by the invention
Fig. 6 is scanning electron microscope (SEM) figure of commercially available Fluoxastrobin
Fig. 7 is the figure of Fluoxastrobin raw material XRPD used in the embodiment of the present invention 1
Fig. 8 is the solvent-free chemical combination of Fluoxastrobin prepared after Fluoxastrobin acetic acid solvate desolventizing in the embodiment of the present invention 8
The XRPD of object schemes.
Specific embodiment
The present invention is further described in detail below with reference to the accompanying drawings and embodiments.It should be appreciated that described herein
Specific embodiment is only used to explain the present invention, is not intended to limit the present invention.Any improvement made on the basis of the present invention
And variation, still within protection scope of the present invention.
Embodiment 1
Steady temperature takes 20g acetic acid to be added in crystallizer at 20 DEG C, and stirring is added, and system is made to keep preferable mixing shape
State.Crystallizer is added in 5g Fluoxastrobin raw material, after adding raw material, continues agitating solution 2h, crosses filter solid, be dried to obtain product.
The X-ray powder diffraction figure of product such as attached drawing 1,7.40 ± 0.20 °, 8.28 ± 0.20 °, 13.26 ± 0.20 °, 14.07 ±
0.20°、14.52±0.20°、18.08±0.20°、18.42±0.20°、18.86±0.20°、20.46±0.20°、21.18
± 0.20 °, 22.14 ± 0.20 °, 22.68 ± 0.20 °, 24.46 ± 0.20 °, 26.88 ± 0.20 °, 28.60 ± 0.20 ° etc.
With characteristic peak, 2 θ=7.40 ± 0.20 ° are starting peak, and the relative intensity of characteristic peak is at 2 θ=21.18 ± 0.20 °
100%.Its TGA result such as Fig. 2, has 13.0% ± 0.5% weightlessness before being heated to 100 DEG C.Its DSC result such as Fig. 3,
There is endothermic peak at 78.9 ± 5 DEG C, has feature melting peak at 110.0 ± 5 DEG C.Its IR result such as Fig. 4,3107,3040,1772,
1705、1408、1376、1277、947、619、510、477cm-1Etc. have characteristic peak.Its SEM result such as Fig. 5 is rodlike crystalline substance
It practises, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size is 40 μm, and angle of repose is 23 °,
It does not coalesce, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 2
25g acetic acid is added in crystallizer at 30 DEG C for steady temperature, and stirring is added, and system is made to keep preferable mixing shape
State.Knot product device is added in 6g Fluoxastrobin raw material, after adding raw material, continues agitating solution 3h, crosses filter solid, be dried to obtain product.
The X-ray powder diffraction figure of product such as Fig. 1.Its TGA and DSC curve such as Fig. 2, Fig. 3.Its infared spectrum (IR) such as Fig. 4.Crystal
Shape with Fig. 5 phase be all it is rodlike, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size is
36 μm, angle of repose is 24 °, is not coalesced, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 3
30g acetic acid is added in crystallizer at 35 DEG C for steady temperature, and stirring is added, and system is made to keep preferable mixing shape
State.Crystallizer is added in 10g Fluoxastrobin raw material, after adding raw material, continues agitating solution 3.5h, crosses filter solid, be dried to obtain production
Product.The X-ray powder diffraction figure of product such as Fig. 1.Its TGA and DSC curve such as Fig. 2, Fig. 3.Its infared spectrum (IR) such as Fig. 4.It is brilliant
Shape with Fig. 5 phase be all it is rodlike, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size
It is 36 μm, angle of repose is 22 °, is not coalesced, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 4
20g acetic acid is added in knot product device at 40 DEG C for steady temperature, and stirring is added, and system is made to keep preferable mixing shape
State.Crystallizer is added in 8g Fluoxastrobin raw material, after adding raw material, continues agitating solution 4h, crosses filter solid, be dried to obtain product.
The X-ray powder diffraction figure of product such as Fig. 1.Its TGA and DSC curve such as Fig. 2, Fig. 3.Its infared spectrum (IR) such as Fig. 4.Crystal
Shape with Fig. 5 phase be all it is rodlike, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size is
39 μm, angle of repose is 23 °, is not coalesced, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 5
20g acetic acid is added in crystallizer at 50 DEG C for steady temperature, and stirring is added, and system is made to keep preferable mixing shape
State.Crystallizer is added in 10g Fluoxastrobin raw material, after adding raw material, continues agitating solution 3.5h, crosses filter solid, be dried to obtain production
Product.The X-ray powder diffraction figure of product such as Fig. 1.Its TGA and DSC curve such as Fig. 2, Fig. 3.Its infared spectrum (IR) such as Fig. 4.It is brilliant
Shape with Fig. 5 phase be all it is rodlike, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size
It is 41 μm, angle of repose is 23 °, is not coalesced, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 6
20g acetic acid is added in knot product device at 60 DEG C for steady temperature, and stirring is added, and system is made to keep preferable mixing shape
State.Crystallizer is added in 12g Fluoxastrobin raw material, after adding raw material, continues agitating solution 4h, crosses filter solid, be dried to obtain product.
The X-ray powder diffraction figure of product such as Fig. 1.Its TGA and DSC curve such as Fig. 2, Fig. 3.Its infared spectrum (IR) such as Fig. 4.Crystal
Shape with Fig. 5 phase be all it is rodlike, surface is smooth.What is illustrated is Fluoxastrobin acetic acid solvate.Its volume average particle size is
36 μm, angle of repose is 24 °, is not coalesced, good fluidity.The Fluoxastrobin raw material crystal form XRPD such as Fig. 7 is crystal form A.
Embodiment 7
Product 1.0g in Example 1 is placed on 80 DEG C of drying boxes, and vacuum degree is maintained at 0.09MPa or so, dries for 24 hours,
XRPD map such as Fig. 8 of solid product analysis is consistent with the XRPD map in Fig. 7, there is identical peak spectral position and shape, passes through
After crossing TG thermogravimetric analysis, the sample after drying, without weightlessness, illustrates that Fluoxastrobin acetic acid solvate is converted into before decomposition temperature
Solvent-free compound.The solvent-free compound of obtained Fluoxastrobin can keep the rodlike of original Fluoxastrobin acetic acid solvate crystal form
Crystal morphology and crystal size size, greatly improve compared to commercial product mobility, and are not easy to coalesce.
Embodiment 8
Product 2.0g in Example 6 is placed on 90 DEG C of drying boxes, and vacuum degree is maintained at 0.08MPa or so, dry 12h,
The XRPD map of solid product analysis is consistent with the XRPD map in Fig. 7, there is identical peak spectral position and shape, by TG heat
After weight analysis, the sample after drying, without weightlessness, it is solvent-free to illustrate that Fluoxastrobin acetic acid solvate is converted into before decomposition temperature
Compound.The solvent-free compound of obtained Fluoxastrobin can keep the rhabdolith shape of original Fluoxastrobin acetic acid solvate crystal form
Looks and crystal size size, greatly improve compared to commercial product mobility, and are not easy to coalesce.
Fluoxastrobin acetic acid solvate provided by the invention can be used for controlling and prevention and treatment is grown on agricultural and garden crop
Fungi, with it has been reported that A, B crystal form mechanism of action it is identical, since its effect has disclosed, Fluoxastrobin acetic acid solvate
Bactericidal effect details are not described herein again.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (8)
1. a kind of Fluoxastrobin acetic acid solvate, which is characterized in that the X-ray that the crystal form is obtained using Cu-K alpha ray measurement
The angle of diffraction that powder diffraction is indicated with 2 angles θ 7.40 ± 0.20 °, 8.28 ± 0.20 °, 13.26 ± 0.20 °, 14.07 ±
0.20°、14.52±0.20°、18.08±0.20°、18.42±0.20°、18.86±0.20°、20.46±0.20°、21.18
± 0.20 °, 22.14 ± 0.20 °, 22.68 ± 0.20 °, 24.46 ± 0.20 °, 26.88 ± 0.20 °, 28.60 ± 0.20 ° etc.
With characteristic peak, wherein the relative intensity of characteristic peak is 100% at 21.18 ± 0.20 °.
2. solvate according to claim 1, which is characterized in that the crystal form is monoclinic system, and space group is P 21/
N, cell parameter are α=
90.00°；β=97.32 (3) °；γ=90 °, unit cell volume are
3. solvate according to claim 1, it is characterised in that the molar ratio of Fluoxastrobin and molecular acid is 1:1, molecule
Formula is C22H17N3O5·C2H4O2, 13.0% ± 0.5% weightlessness is had before being heated to 100 DEG C.
4. solvate according to claim 1, it is characterised in that differential scanning calorimetric analysis (DSC) map 78.9 ±
5 DEG C have endothermic peak, have feature melting peak at 110.0 ± 5 DEG C.
5. solvate according to claim 1, which is characterized in that infared spectrum 3107,3040,1772,1705,
1408、1376、1277、947、619、510、477cm-1Etc. have characteristic peak.
6. the preparation method of the Fluoxastrobin acetic acid solvate of -5 any one according to claim 1, is suspended using constant temperature
Rotating crystal method preparation, Fluoxastrobin is added in acetic acid, and the mass ratio of Fluoxastrobin and solvent acetic acid is 1:0.4~4, and constant temperature, which suspends, to be turned
Brilliant temperature is 20 DEG C~60 DEG C, stirs 2h~6h, generates white solid, filtering product, it is molten to be drying to obtain Fluoxastrobin acetic acid while hot
Agent compound.
7. Fluoxastrobin acetic acid solvate is used to prepare the solvent-free compound of Fluoxastrobin.
8. application as claimed in claim 7, the method for preparing the solvent-free compound of Fluoxastrobin is: by Fluoxastrobin acetic acid solvate
60 DEG C~100 DEG C, 0.08MPa~0.1MPa under the conditions of it is dry, obtain the solvent-free compound of Fluoxastrobin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810573514.4A CN108947914B (en) | 2018-06-06 | 2018-06-06 | Azoxystrobin acetic acid solvate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810573514.4A CN108947914B (en) | 2018-06-06 | 2018-06-06 | Azoxystrobin acetic acid solvate and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108947914A true CN108947914A (en) | 2018-12-07 |
| CN108947914B CN108947914B (en) | 2021-07-23 |
Family
ID=64493020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810573514.4A Active CN108947914B (en) | 2018-06-06 | 2018-06-06 | Azoxystrobin acetic acid solvate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108947914B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111742927A (en) * | 2019-03-27 | 2020-10-09 | Upl有限公司 | Azoxystrobin solvate and preparation method thereof |
| CN111747899A (en) * | 2019-03-27 | 2020-10-09 | 华东理工大学 | Azoxystrobin channel solvate, eutectic and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL181125A0 (en) * | 2007-02-01 | 2007-07-04 | Maktheshim Chemical Works Ltd | Polymorphs of 3-(e)-2-{2-[6-(2- |
| CN109384728A (en) * | 2017-08-07 | 2019-02-26 | 华东理工大学 | Fluoxastrobin channel solvates and preparation method thereof |
-
2018
- 2018-06-06 CN CN201810573514.4A patent/CN108947914B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111742927A (en) * | 2019-03-27 | 2020-10-09 | Upl有限公司 | Azoxystrobin solvate and preparation method thereof |
| CN111747899A (en) * | 2019-03-27 | 2020-10-09 | 华东理工大学 | Azoxystrobin channel solvate, eutectic and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108947914B (en) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pando et al. | Preparation of pharmaceutical co-crystals through sustainable processes using supercritical carbon dioxide: a review | |
| JP2508949B2 (en) | Crystal of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for producing the same | |
| CN108947914A (en) | Fluoxastrobin acetic acid solvate and preparation method | |
| CN110248660A (en) | The happy solid-state form cut down for Buddhist nun of methanesulfonic acid | |
| US20090281315A1 (en) | Forms of lapatinib ditosylate and processes for preparation thereof | |
| CN103755723B (en) | A kind of preparation method of rifampicin I crystal form | |
| CN108947915A (en) | Fluoxastrobin acetone solvate and preparation method | |
| CN107849007A (en) | Crystal formation of bilastine and preparation method thereof | |
| CN108675963A (en) | Fluoxastrobin Isosorbide-5-Nitrae dioxane solvent compound and preparation method | |
| CN107652199A (en) | A kind of preparation method of crystal type N AAAs | |
| JP5570520B2 (en) | Process for preparing non-hydrated crystal forms | |
| US20020107275A1 (en) | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation | |
| CN110041320B (en) | Preparation method of azilsartan crystals | |
| CN103755609B (en) | Crystal formation of tartaric acid valnemulin and preparation method thereof | |
| CN106046086B (en) | It is a kind of to prepare the unformed method of tylonolide | |
| CN111303097A (en) | Crystal form C of michelia lactone fumarate dimethylamine and preparation method thereof | |
| CN111303099A (en) | Sphaelactone dimethylamine fumarate crystal form F and preparation method thereof | |
| CN109180494A (en) | pentanediamine succinate and its crystal | |
| CN103980166B (en) | A kind of novel crystal forms of florfenicol and preparation method thereof | |
| CA3181785A1 (en) | Solid state forms of cyantraniliprole | |
| CN106083904B (en) | A kind of complex with low temperature phase change of calcic, preparation method and applications | |
| CN107759670A (en) | Crystallization of aerosporin 1, B2 or its mixture and preparation method thereof | |
| KR20150079043A (en) | Process for Preparation and Conversion of Taltirelin Crystalline Form α | |
| AU745058B2 (en) | Method of purifying carbazole ester precursors of 6-chloro-alpha-methyl-carbazole-2-acetic acid | |
| CN104109159A (en) | New crystal forms of benzene sulfonamide thiazole and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |